Increased rhabdomyolysis-related adverse events in higher dosages. Monitor for early signs of rhabdomyolysis eg, CPK elevation, myoglobinuria, myalgia & weakness. Family history of or w/ hypothyroidism, hereditary muscular disorders (eg, muscular dystrophy); history of drug-induced myopathy. Alcoholism. Consider dietary advice, exercise therapy & reduction of risk factors of ischemic heart diseases eg, HTN & smoking. Perform LFTs once or more during the 1st 12 wk of treatment, & periodically, thereafter (once every 6 mth, or more frequently). Regularly test plasma lipid levels, & discontinue if there is no response to treatment. Immune-mediated necrotising myopathy may occur upon discontinuation of treatment & may be managed by immunosuppressants. Concomitant use w/ fibrates (eg, bezafibrate) & niacin. Hepatic & renal impairment. Do not administer to women who may be pregnant or during pregnancy & lactation. Childn. Elderly.
Sign Out
